Healthcare News

FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for...

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70%...

Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED...

RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has reduced the wait for the first available echocardiography appointment at its...

Enterome Phase 1/2 data show OncoMimics™ EO4010-induced CD8 T-cell expansion was associated with longer survival in patients with colorectal cancer

EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients...

Louvain-la-Neuve, Belgium, October 23, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial...

Louvain-la-Neuve, Belgique, le 23 octobre 2026, 7h00 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et des solutions de faisceaux...

Pratteln, Switzerland, October 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes that its licensing partner Nxera Pharma Co., Ltd. (“Nxera”) has submitted a Marketing Authorization...

Pratteln, Schweiz, 23. Oktober 2026 – Santhera Pharmaceuticals (SIX: SANN) gibt heute bekannt, dass sein Lizenzpartner Nxera Pharma Co., Ltd. (“Nxera“) beim südkoreanischen Ministerium für...